Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $2.12 in the prior trading day, ImmunityBio Inc (NASDAQ: IBRX) closed at $2.13, up 0.47%. In other words, the price has increased by $0.47 from its previous closing price. On the day, 10.63 million shares were traded. IBRX stock price reached its highest trading level at $2.14 during the session, while it also had its lowest trading level at $2.0.
Ratios:
Our goal is to gain a better understanding of IBRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.65 and its Current Ratio is at 5.77.
On March 06, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $8.
On January 10, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $6.BTIG Research initiated its Buy rating on January 10, 2025, with a $6 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IBRX now has a Market Capitalization of 2097975936 and an Enterprise Value of 2702360832. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.41. Its current Enterprise Value per Revenue stands at 32.734 whereas that against EBITDA is -11.032.
Stock Price History:
The Beta on a monthly basis for IBRX is 0.00, which has changed by -0.6091743 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, IBRX has reached a high of $5.88, while it has fallen to a 52-week low of $1.83. The 50-Day Moving Average of the stock is -14.08%, while the 200-Day Moving Average is calculated to be -21.47%.
Shares Statistics:
The stock has traded on average 9.84M shares per day over the past 3-months and 9536790 shares per day over the last 10 days, according to various share statistics. A total of 984.97M shares are outstanding, with a floating share count of 303.30M. Insiders hold about 89.60% of the company’s shares, while institutions hold 14.01% stake in the company. Shares short for IBRX as of 1760486400 were 72564054 with a Short Ratio of 7.38, compared to 1757894400 on 84559728. Therefore, it implies a Short% of Shares Outstanding of 72564054 and a Short% of Float of 21.93.
Earnings Estimates
A detailed examination of ImmunityBio Inc (IBRX) is currently in progress, with 3.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.11 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.38 and -$0.51 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.28, with 3.0 analysts recommending between -$0.26 and -$0.3.
Revenue Estimates
5 analysts predict $35.89M in revenue for. The current quarter. It ranges from a high estimate of $47.64M to a low estimate of $30M. As of. The current estimate, ImmunityBio Inc’s year-ago sales were $7.55MFor the next quarter, 5 analysts are estimating revenue of $30M. There is a high estimate of $30M for the next quarter, whereas the lowest estimate is $30M.
A total of 5 analysts have provided revenue estimates for IBRX’s current fiscal year. The highest revenue estimate was $128.7M, while the lowest revenue estimate was $100.44M, resulting in an average revenue estimate of $111.17M. In the same quarter a year ago, actual revenue was $14.74MBased on 5 analysts’ estimates, the company’s revenue will be $221.5M in the next fiscal year. The high estimate is $279.4M and the low estimate is $140.83M.
